Watson Pharmaceuticals Inc  (WPI)
Other Ticker:  
    Sector  Consumer Non Cyclical    Industry Legacy
   Industry Legacy
   Sector  Consumer Non Cyclical
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00

 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 128
 Employees -
 Revenues (TTM) (Millions $) 5,709
 Net Income (TTM) (Millions $) 164
 Cash Flow (TTM) (Millions $) 59
 Capital Exp. (TTM) (Millions $) 124

Watson Pharmaceuticals Inc
Watson Pharmaceuticals, Inc., is engaged in the development, manufacture, marketing, sale and distribution of branded and off-patent (generic) pharmaceutical products.  We also develop advanced drug delivery systems designed to enhance the therapeutic benefits of existing drug forms. Watson operates manufacturing, distribution, research and development, and administrative facilities primarily in the United States of America (U.S.).

Watson was incorporated in 1985 and began operations as a manufacturer and marketer of off-patent pharmaceuticals. In February 1993, we completed our initial public offering. Through internal product development and acquisitions of products and businesses, we have grown into a diversified specialty pharmaceutical company. 

Prescription pharmaceutical products in the U.S. are generally marketed as either brand or generic pharmaceuticals. Branded pharmaceutical products are marketed under brand names through programs that are designed to generate physician and consumer loyalty. Generic pharmaceutical products are bioequivalents of their respective branded products and provide a cost-efficient alternative to branded products. As a result of the differences between the two types of products, we operate and manage our business as two segments: branded and generic pharmaceutical products.

Branded Pharmaceutical Products

Newly developed pharmaceutical products are normally patented and, as a result, generally are offered by a single provider when first introduced to the market.  We currently market a number of patented products to physicians, hospitals, and other markets that we serve. We also market certain trademarked off-patent products directly to healthcare professionals. We classify these patented and off-patent trademarked products as our branded pharmaceutical products. 


Our Women’s Health product lines include oral contraceptives, a genital warts treatment, a hormone replacement therapy and a visual cervical screening device.  Currently, we have a total of 17 oral contraceptives in our product portfolio.  We market our Women’s Health products primarily to obstetricians and gynecologists.


We sell our branded and generic pharmaceutical products primarily to drug wholesalers, retailers and distributors, including large chain drug stores, hospitals, clinics, government agencies and managed healthcare providers such as health maintenance organizations and other institutions. These customers comprise a significant part of the distribution network for pharmaceutical products in the U.S. This distribution network is continuing to undergo significant consolidation marked by mergers and acquisitions among wholesale distributors and the growth of large retail drug store chains. As a result, a small number of large, wholesale distributors controls a significant share of the market, and the number of independent drug stores and small drug store chains has decreased. We expect that consolidation of drug wholesalers and retailers will impact pricing and create other competitive pressures on drug manufacturers.

Our largest customers are: AmeriSourceBergen Corp, McKesson HBOC, Cardinal Health, Inc., Walgreen Co.


The pharmaceutical industry is highly competitive. We compete with different companies depending upon product categories, and within each product category, upon dosage strengths and drug delivery systems. Such competitors include the major brand name and generic manufacturers of pharmaceutical products, especially those doing business in the U.S. In addition to product development, other competitive factors in the pharmaceutical industry include product quality and price, reputation and service and access to proprietary and technical information. It is possible that developments by others will make our products or technologies noncompetitive or obsolete.

Competing in the branded product business requires us to identify and quickly bring to market new products embodying technological innovations. Successful marketing of branded products depends primarily on the ability to communicate the effectiveness, safety and value to healthcare professionals in private practice, group practices and managed care organizations. We anticipate that our branded product offerings will support our existing areas of therapeutic focus. Based upon business conditions and other factors, we regularly reexamine our business strategies and may from time to time reallocate our resources from one therapeutic area to another, withdraw from a therapeutic area or add an additional therapeutic area in order to maximize our overall growth opportunities.

Our competitors in branded products include the major brand name manufacturers of pharmaceuticals such as Johnson & Johnson, Wyeth and Pfizer. Based on total assets, annual revenues and market capitalization, we are considerably smaller than these and other national competitors in the branded product area.  These competitors, as well as others, have been in business for a longer period of time, have a greater number of products on the market and have greater financial and other resources than we do. If we directly compete with them for the same markets and/or products, their financial strength could prevent us from capturing a meaningful share of those markets.

We actively compete in the generic pharmaceutical business. Revenues and gross profit derived from the sales of generic pharmaceutical products tend to follow a pattern based on certain regulatory and competitive factors. As patents and regulatory exclusivity for brand name products expire, the first off-patent manufacturer to receive regulatory approval for generic equivalents of such products is generally able to achieve significant market penetration. As competing off-patent manufacturers receive regulatory approvals on similar products, market share, revenues and gross profit typically decline, in some cases, dramatically.  Accordingly, the level of market share, revenues and gross profit attributable to a particular generic product is normally related to the number of competitors in that product’s market and the timing of that product’s regulatory approval and launch, in relation to competing approvals and launches. Consequently, we must continue to develop and introduce new products in a timely and cost-effective manner to maintain our revenues and gross profit. In addition to competition from other generic drug manufacturers, we face competition from brand name companies in the generic market. Many of these companies seek to participate in sales of generic products by, among other things, collaborating with other generic pharmaceutical companies or by marketing their own generic equivalent to their branded products. Our major competitors in generic products include Teva Pharmaceutical Industries, Ltd., Barr Laboratories, Inc., Mylan Laboratories, Inc., Andrx Corporation, IVAX Corporation and Sandoz Pharmaceuticals, a division of Novartis.


Customers Net Income fell by WPI's Customers Net Profit Margin fell to

-23.74 %

3.46 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

Year to Date Decrease / Increase
ABBV        9.31% 
ABT   -17.27%    
JNJ        4.61% 
LLY        11.36% 
MRK        22.06% 
PFE   -6.65%    
• View Complete Report

Sun Pacific Holding Corp

Breathtaking numbers, by Sun Pacific Holding Corp in the first quarter of 2022 earnings season

In the first quarter of 2022 earnings season Sun Pacific Holding Corp reached break-even of $0.00 per share compared to $-0.00 a year ago and from $0.00 per share from the previous quarter.

Stemtech Corporation

Deficit Bigger Than a Year Ago but Revenues Unchanged at Stemtech Corporation in the financial time-frame ending Mar 31 2022

In the financial time-frame ending Mar 31 2022 Stemtech Corporation loss increased of $-0.01 per share compared to $-0.00 a year ago and improved from $-0.02 per share from the previous quarter.

Vivos Therapeutics Inc.

Logged a Loss by Vivos Therapeutics Inc in the first quarter of 2022 earnings season statement

In the first quarter of 2022 earnings season Vivos Therapeutics Inc lost money of $-0.26 per share compared to $-0.96 a year ago and eps fell from $0.43 per share from the previous quarter.

Ezagoo Limited

Ezagoo Limited announced very difficult period in the fiscal first quarter of 2022

Ezagoo Limited recorded operating loss of $-0.180595 millions, in the fiscal first quarter of 2022, a degradation from the operating profit of $0.298338 millions, reported in first quarter of 2021

Stem Holdings Inc.

Severe hit for Stem Holdings Inc in the second quarter of 2022

In the second quarter of 2022 Stem Holdings Inc lost money of $-0.02 per share compared to $-0.06 a year ago and from $-0.02 per share from the previous quarter.


Watson Pharmaceuticals Inc's Segments
Branded pharmaceutical products
 Segment    9.44 % of total Revenue
Generic pharmaceutical products
 Segment    71.65 % of total Revenue
 Segment    18.91 % of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Watson Pharmaceuticals Inc does not provide revenue guidance.

Earnings Outlook
Stem Holdings Inc. does not provide earnings estimates.

Geographic Revenue Dispersion
United States 88.78 %
International 11.22 %


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production


Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales


Event Calendar

BPTH's Profile

Stock Price

BPTH's Financials

Business Description


Charts & Quotes

BPTH's News


BPTH's Competitors

Customers & Markets

Economic Indicators

BPTH's Growth

Company Segments


Stock Performance

Growth Rates




Financial Strength


Largest Companies

Management Effectivness


At a Glance


Growth Rates



Financial Strength


At a Glance



Sectors & Industries






About us


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2022 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071